Targanta Releases Antibiotic Data

Xconomy Boston — 

Targanta Therapeutics (NASDAQ:TARG) has released detailed data from its Phase 2 study of its antibiotic oritavancin in single or infrequent doses, showing that the fewer doses were as safe and effective as a three-to-seven day course of therapy, according to the Cambridge, MA-based firm. Luke wrote earlier this month about Targanta’s hoped-for FDA approval of oritavancin—which is intended to treat skin infections, including those cause by antibiotic-resistant bugs such as MRSA—this year.